Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

about

Racial Disparities in the Molecular Landscape of Cancer.

P2860

Q52723102-575A9367-DD3C-4CBF-9C57-1A1437887D29

P2860

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

Item

http://www.wikidata.org/entity/Q38669870

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

@en

type

Item

label

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

@en

prefLabel

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

@en

P1476

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

@en

P2093

David Arguello

http://www.w3.org/2001/XMLSchema#string

Gregory M Heestand

http://www.w3.org/2001/XMLSchema#string

Zoran Gatalica

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co

P304

80-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2017.06.019

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Maria Schwaederle

P577

2017-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28728050

http://www.w3.org/2001/XMLSchema#string

P932

5613945

http://www.w3.org/2001/XMLSchema#string

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

about

P2860

P2860

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932